Triple

T5289292
Position Surface form Disambiguated ID Type / Status
Subject Norwegian Medicines Agency E119701 entity
Predicate participatesIn P149 FINISHED
Object European medicines regulatory network E387633 NE FINISHED

Named-entity recognition

Before disambiguation, gpt-5-mini classified whether the object phrase is a named entity — the step behind the object's NE type shown above.

Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: European medicines regulatory network | Statement: [Norwegian Medicines Agency, participatesIn, European medicines regulatory network]

Disambiguation candidates (1 decision)

The exact options the model was shown at each disambiguation step, with the option it chose highlighted — the evidence behind this triple's disambiguated ids.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: European medicines regulatory network
Context triple: [Norwegian Medicines Agency, participatesIn, European medicines regulatory network]
  • A. European medicines regulatory authorities chosen
    European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
  • B. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • C. European Directorate for the Quality of Medicines & HealthCare
    The European Directorate for the Quality of Medicines & HealthCare is a Council of Europe body responsible for developing quality standards and guidance to ensure the safety and efficacy of medicines and improve healthcare across member states.
  • D. Committee for Medicinal Products for Human Use
    The Committee for Medicinal Products for Human Use is the European Medicines Agency’s expert body responsible for evaluating and providing scientific opinions on the safety, quality, and efficacy of medicines for human use in the European Union.
  • E. European Union pharmaceutical legislation
    European Union pharmaceutical legislation is the body of EU laws and regulations that governs the authorization, supervision, safety, and quality of medicines for human and veterinary use across member states.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

Stage Batch ID Job type Status
creating batch_69bd446de5648190b313a90bd96730d2 elicitation completed
NER batch_69bd84dcd6908190b35bf9c371965bc9 ner completed
NED1 batch_69bf10dfc2948190b65f5e4c9388a5cb ned_source_triple completed
Created at: March 20, 2026, 1:52 p.m.